Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MAPK1/ERK2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Kinase | MAPK1/ERK2 Wild-Type Recombinant Protein Sequence Verified, High Purity (>95%), Endotoxin <1EU/μg. Suitable for kinase assays. |
View MAPK1 Products |
| Selectivity Panel | MAPK3/ERK1 Recombinant Protein Paralog for isoform specificity screening (83% homology), High Purity, Sequence Verified. |
View MAPK3 Products |
| Resistance Mutant | MAPK1/ERK2 Q56P Mutant Protein Clinically observed MEK inhibitor resistance mutation. Sequence Verified against COSMIC database. |
View MAPK1 Products |
| Upstream Cascade | MAP2K1/MEK1 Recombinant Protein For in vitro pathway reconstitution and combination studies. |
View MAP2K1 Products |
| Detection Reagent | Anti-MAPK1/ERK2 Antibody (Rabbit Monoclonal) High affinity, suitable for Western Blot and IP. |
View MAPK1 Products |
| Gene Delivery | MAPK1/ERK2 ORF Lentivirus Full-length ORF for stable cell line generation. High titer. |
View MAPK1 Products |
| Validator | MAPK1 siRNA Set (3 unique sequences) For knockdown verification and assay specificity control. |
View MAPK1 Products |
| Related Target | DUSP6 (MKP3) ERK-specific phosphatase, critical negative regulator for pathway studies. |
View DUSP6 Products |
| Related Target | MAPK3/ERK1 Co-therapeutic target for dual ERK1/2 inhibition strategies. |
View MAPK3 Products |
| Related Target | BRAF Upstream kinase driving MAPK pathway hyperactivation, often mutated in melanoma. |
View BRAF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ERK1 vs ERK2 Isoform Selectivity | Paired human MAPK1 & MAPK3 proteins (>95% purity) for parallel screening; strict mass spec identity confirmation. |
| Drug Resistance Mutation Profiling | Recombinant Q56P and other clinic-derived mutants available; Sequence Verified against COSMIC database. |
| Kinase Activity Standardization | Endotoxin-controlled (<1EU/μg) proteins suitable for sensitive ATP-competition assays (HTRF/ADP-Glo). |
| Pathway Reconstitution | Active MAP2K1 (MEK1) available for coupled enzyme cascade validation. |
Live MAPK1/ERK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAPK1/ERK2 therapeutics is intensifying, with major players shifting focus from upstream inhibitors (BRAF/MEK) to direct ERK1/2 inhibition and proteolysis-targeting chimeras (PROTACs) to combat acquired resistance. As first-generation MEK/BRAF therapies face clinical limitations due to pathway reactivation, the next wave of R&D is targeting ERK2 directly as the terminal node of the MAPK signaling cascade, emphasizing vertical pathway inhibition and resistance mutation management. The therapeutic focus has evolved from monotherapy to rational combination regimens with KRAS, RAF, and MEK inhibitors, as well as allosteric ERK inhibitors designed to overcome ATP-competitive resistance. Future outlook points toward selective degradation (PROTAC) and mutant-selective small molecules for precision oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ATP-Competitive Inhibitors | BioMed Valley (Ulixertinib/BVD-523), Merck (KO-947) | Melanoma, Pancreatic, Colorectal | Kinase Activity Assay (Need active WT protein with verified ATP-binding capacity) |
| Combination (MEK + ERK) | Pfizer/Array, Novartis, Roche, AstraZeneca | RAS-mutant Solid Tumors, Refractory NSCLC | Synergy Screening Panel (Need purified ERK2 + MEK1 + ERK1 for selectivity matrix) |
| PROTAC Degraders | Kymera, Seed Therapeutics, Emerging Biotechs | KRAS/BRAF mutant cancers, Resistance Settings | Target Engagement & Mutant Binding (Need mutant protein panel for ternary complex formation) |
| Allosteric Inhibitors | Preclinical (Academic/Biotech) | Refractory Mutations | Conformation-Specific Binding Assay (Need non-ATP-site quality control) |